Tirdzniecība Biodesix, Inc. - BDSX CFD
Pievienot izlasei- Kopsavilkums
- Vēsturiskie Dati
- Notikumi
- Peļņas Atskaite
- Bilance
- Naudas Plūsma
- Īpašums
Tirdzniecības Nosacījumi
| Starpība | 0.0556 | ||||||||
|
Garās pozīcijas nodeva naktij
Long position overnight fee
Doties uz platformu | -0.024068% | ||||||||
|
Īsās pozīcijas nodeva naktij
Short position overnight fee
Doties uz platformu | 0.001846% | ||||||||
| Nakts laika nodeva | 21:00 (UTC) | ||||||||
| Min. tirgotais daudzums | 1 | ||||||||
| Valūta | USD | ||||||||
| Drošības rezerve | 20% | ||||||||
| Fondu birža | United States of America | ||||||||
| Tirdzniecības komisija | 0% |
*Information provided by Capital.com
Galvenie Statistikas Dati
| Iepriekš. aizvērt* | 1.7072 |
| Atvērt* | 1.6873 |
| Izmaiņas par 1 gadu* | -7.8% |
| Dienas Diapazons* | 1.6873 - 1.7372 |
| 52 ned Diapazons | 0.96-3.00 |
| Vidējais apjoms (10 dienas) | 142.92K |
| Vidējais apjoms (3 mēneši) | 2.52M |
| Tirgus Kapitalizācija | 134.90M |
| Cenas/Peļņas Attiecība | -100.00K |
| Izvietotās Akcijas | 77.97M |
| Ieņēmumi | 38.21M |
| EPS | -1.60 |
| Dividende (Ienesīgums %) | N/A |
| Beta | -100.00K |
| Nākamās Peļņas Datums | May 9, 2023 |
"Visus datus nodrošina Refinitiv, izņemot datus, kas atzīmēti ar zvaigznīti, kas ir *dati, kurus nodrošina Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Aizvēršana | Change | Change (%) | Atvēršana | High | Low |
|---|---|---|---|---|---|---|
| Mar 28, 2023 | 1.7172 | 0.0100 | 0.59% | 1.7072 | 1.7372 | 1.6473 |
| Mar 27, 2023 | 1.7072 | -0.0200 | -1.16% | 1.7272 | 1.7272 | 1.6773 |
| Mar 24, 2023 | 1.7073 | 0.0800 | 4.92% | 1.6273 | 1.7073 | 1.6273 |
| Mar 23, 2023 | 1.6174 | -0.2596 | -13.83% | 1.8770 | 1.8770 | 1.6074 |
| Mar 22, 2023 | 1.8570 | 0.0799 | 4.50% | 1.7771 | 1.8969 | 1.7472 |
| Mar 21, 2023 | 1.7771 | 0.0300 | 1.72% | 1.7471 | 1.7871 | 1.7372 |
| Mar 20, 2023 | 1.7172 | -0.0399 | -2.27% | 1.7571 | 1.7771 | 1.6173 |
| Mar 17, 2023 | 1.7571 | -0.0300 | -1.68% | 1.7871 | 1.8670 | 1.7472 |
| Mar 16, 2023 | 1.7871 | -0.0799 | -4.28% | 1.8670 | 1.9070 | 1.7172 |
| Mar 15, 2023 | 1.8770 | 0.2896 | 18.24% | 1.5874 | 1.8870 | 1.5874 |
| Mar 14, 2023 | 1.6373 | -0.0100 | -0.61% | 1.6473 | 1.6973 | 1.6274 |
| Mar 13, 2023 | 1.6473 | 0.1498 | 10.00% | 1.4975 | 1.7172 | 1.4975 |
| Mar 10, 2023 | 1.5675 | 0.1398 | 9.79% | 1.4277 | 1.6573 | 1.3877 |
| Mar 9, 2023 | 1.4776 | -0.2096 | -12.42% | 1.6872 | 1.6873 | 1.4676 |
| Mar 8, 2023 | 1.6673 | -0.0898 | -5.11% | 1.7571 | 1.7971 | 1.6673 |
| Mar 7, 2023 | 1.7771 | 0.0599 | 3.49% | 1.7172 | 1.7971 | 1.7172 |
| Mar 6, 2023 | 1.7572 | -0.3194 | -15.38% | 2.0766 | 2.1366 | 1.7172 |
| Mar 3, 2023 | 1.9668 | 0.0000 | 0.00% | 1.9668 | 2.0467 | 1.9668 |
| Mar 2, 2023 | 1.9668 | -0.0300 | -1.50% | 1.9968 | 2.0368 | 1.9569 |
| Mar 1, 2023 | 1.9868 | -0.0399 | -1.97% | 2.0267 | 2.0467 | 1.9369 |
Biodesix, Inc. Events
| Laiks (UTC) (UTC) | Valsts | Notikums |
|---|---|---|
| No events scheduled | ||
- Ikgadējs
- Ceturkšņa
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Kopējie ienākumi | 38.212 | 54.506 | 45.557 | 24.552 | 20.432 |
| Ienākumi | 38.212 | 54.506 | 45.557 | 24.552 | 20.432 |
| Cost of Revenue, Total | 14.154 | 30.518 | 21.998 | 6.074 | 4.406 |
| Bruto Peļņa | 24.058 | 23.988 | 23.559 | 18.478 | 16.026 |
| Kopējie Darbības Izdevumi | 95.78 | 93.148 | 68.491 | 51.293 | 44.095 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 58.458 | 47.958 | 32.328 | 30.637 | 25.899 |
| Pētniecība un Attīstība | 13.102 | 12.789 | 10.818 | 10.468 | 8.188 |
| Neparedzēti Izdevumi (Ienākumi) | 7.062 | -2.298 | 3.451 | 1.739 | |
| Other Operating Expenses, Total | 0 | 1.622 | 0.818 | 0.663 | 3.863 |
| Darbības Izdevumi | -57.568 | -38.642 | -22.934 | -26.741 | -23.663 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | -8.072 | -4.508 | -7.586 | -2.953 | -2.892 |
| Citi, Neto | 0.193 | -0.009 | -0.83 | -1.032 | 0.389 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | -65.447 | -43.159 | -31.35 | -30.726 | -26.166 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | -65.447 | -43.159 | -31.35 | -30.726 | -26.166 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | -65.447 | -43.159 | -31.35 | -30.726 | -26.166 |
| Neto Ienākumi | -65.447 | -43.159 | -31.35 | -30.726 | -26.166 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -65.447 | -43.159 | -31.35 | -30.726 | -26.166 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -65.447 | -43.159 | -31.35 | -30.726 | -26.166 |
| Atšķaidītie Neto Ienākumi | -65.447 | -43.159 | -31.35 | -30.726 | -26.166 |
| Atšķaidītie Ienākumi par Akcijām | 42.103 | 27.365 | 26.5615 | 26.2541 | 26.2541 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -1.55445 | -1.57716 | -1.18028 | -1.17033 | -0.99665 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
| Atšķaidītā Normalizētā Peļņa par Akciju | -1.38672 | -1.66114 | -1.14948 | -1.03889 | -0.93041 |
| Depreciation / Amortization | 3.004 | 2.559 | 2.529 |
| Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
|---|---|---|---|---|---|
| Kopējie ienākumi | 9.607 | 11.107 | 10.95 | 6.548 | 7.224 |
| Ienākumi | 9.607 | 11.107 | 10.95 | 6.548 | 7.224 |
| Cost of Revenue, Total | 3.306 | 3.633 | 3.98 | 3.235 | 2.493 |
| Bruto Peļņa | 6.301 | 7.474 | 6.97 | 3.313 | 4.731 |
| Kopējie Darbības Izdevumi | 27.474 | 21.769 | 25.528 | 21.009 | 19 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 16.626 | 15.114 | 15.235 | 14.487 | 13.558 |
| Pētniecība un Attīstība | 3.565 | 2.97 | 3.361 | 3.206 | 2.852 |
| Neparedzēti Izdevumi (Ienākumi) | 3.977 | 0.052 | 2.952 | 0.081 | 0.097 |
| Darbības Izdevumi | -17.867 | -10.662 | -14.578 | -14.461 | -11.776 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | -2.55 | -3.039 | -1.346 | -1.137 | -1.496 |
| Citi, Neto | 0.079 | 0.002 | 0.1 | 0.012 | -0.01 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | -20.338 | -13.699 | -15.824 | -15.586 | -13.282 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | -20.338 | -13.699 | -15.824 | -15.586 | -13.282 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | -20.338 | -13.699 | -15.824 | -15.586 | -13.282 |
| Neto Ienākumi | -20.338 | -13.699 | -15.824 | -15.586 | -13.282 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -20.338 | -13.699 | -15.824 | -15.586 | -13.282 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -20.338 | -13.699 | -15.824 | -15.586 | -13.282 |
| Atšķaidītie Neto Ienākumi | -20.338 | -13.699 | -15.824 | -15.586 | -13.282 |
| Atšķaidītie Ienākumi par Akcijām | 57.553 | 40.448 | 39.239 | 31.07 | 27.059 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -0.35338 | -0.33868 | -0.40327 | -0.50164 | -0.49085 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
| Atšķaidītā Normalizētā Peļņa par Akciju | -0.28428 | -0.3374 | -0.32804 | -0.49903 | -0.48727 |
| Other Operating Expenses, Total | 0 | 0 | 0 | 0 | 0 |
- Ikgadējs
- Ceturkšņa
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 43.613 | 86.14 | 12.7 | 9.913 |
| Nauda un Īstermiņa Ieguldījumi | 32.712 | 62.126 | 5.286 | 5.914 |
| Nauda un Ekvivalenti | 32.712 | 62.126 | 5.286 | 5.914 |
| Debitoru Parādu Kopsumma, Neto | 3.656 | 15.304 | 5.292 | 1.892 |
| Accounts Receivable - Trade, Net | 3.656 | 15.304 | 5.292 | 1.892 |
| Other Current Assets, Total | 7.245 | 8.71 | 2.122 | 2.107 |
| Total Assets | 76.097 | 121.07 | 41.633 | 39.057 |
| Property/Plant/Equipment, Total - Net | 4.179 | 3.178 | 2.12 | 1.388 |
| Property/Plant/Equipment, Total - Gross | 10.928 | 9.902 | 8.506 | 6.956 |
| Accumulated Depreciation, Total | -6.749 | -6.724 | -6.386 | -5.568 |
| Goodwill, Net | 15.031 | 15.031 | 11.631 | 10.804 |
| Intangibles, Net | 11.617 | 13.26 | 15.092 | 16.852 |
| Other Long Term Assets, Total | 1.657 | 3.461 | 0.09 | 0.1 |
| Total Current Liabilities | 28.96 | 32.125 | 22.6 | 4.468 |
| Accounts Payable | 1.662 | 8.964 | 1.717 | 0.886 |
| Accrued Expenses | 4.899 | 4.69 | 1.899 | 1.568 |
| Notes Payable/Short Term Debt | 0 | 0 | 12.045 | 0 |
| Other Current Liabilities, Total | 22.38 | 6.631 | 6.939 | 2.014 |
| Total Liabilities | 56.37 | 79.904 | 76.213 | 53.125 |
| Total Long Term Debt | 9.993 | 15.926 | 23.812 | 23.099 |
| Long Term Debt | 9.993 | 15.926 | 23.812 | 23.099 |
| Other Liabilities, Total | 17.417 | 31.853 | 29.801 | 25.558 |
| Total Equity | 19.727 | 41.166 | -34.58 | -14.068 |
| Redeemable Preferred Stock | 0 | 0 | 193.959 | 183.962 |
| Common Stock | 0.031 | 0.027 | 0.001 | 0.001 |
| Additional Paid-In Capital | 321.669 | 299.953 | 2.324 | 2.107 |
| Retained Earnings (Accumulated Deficit) | -301.973 | -258.814 | -230.864 | -200.138 |
| Total Liabilities & Shareholders’ Equity | 76.097 | 121.07 | 41.633 | 39.057 |
| Total Common Shares Outstanding | 30.7896 | 26.5615 | 26.2541 | 26.2541 |
| Current Port. of LT Debt/Capital Leases | 0.019 | 11.84 | 0 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 27.233 | 43.613 | 56.445 | 68.45 | 81.244 |
| Nauda un Īstermiņa Ieguldījumi | 16.427 | 32.712 | 47.913 | 56.349 | 55.329 |
| Nauda un Ekvivalenti | 16.427 | 32.712 | 47.913 | 56.349 | 55.329 |
| Debitoru Parādu Kopsumma, Neto | 3.774 | 3.656 | 2.784 | 5.281 | 18.367 |
| Accounts Receivable - Trade, Net | 3.774 | 3.656 | 2.784 | 5.281 | 18.367 |
| Other Current Assets, Total | 7.032 | 7.245 | 5.748 | 6.82 | 7.548 |
| Total Assets | 61.651 | 76.097 | 89.997 | 101.804 | 115.486 |
| Property/Plant/Equipment, Total - Net | 6.247 | 4.179 | 4.432 | 3.378 | 3.387 |
| Property/Plant/Equipment, Total - Gross | 13.409 | 10.928 | 11.827 | 10.471 | 10.369 |
| Accumulated Depreciation, Total | -7.162 | -6.749 | -7.395 | -7.093 | -6.982 |
| Goodwill, Net | 15.031 | 15.031 | 15.031 | 15.031 | 15.031 |
| Intangibles, Net | 11.131 | 11.617 | 11.992 | 12.4 | 12.821 |
| Other Long Term Assets, Total | 2.009 | 1.657 | 2.097 | 2.545 | 3.003 |
| Total Current Liabilities | 29.811 | 28.96 | 22.787 | 21.272 | 16.124 |
| Accounts Payable | 2.12 | 1.662 | 1.6 | 1.16 | 3.747 |
| Accrued Expenses | 4.597 | 4.899 | 3.533 | 2.959 | 2.622 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.051 | 0.019 | 0.02 | 3.106 | 2.707 |
| Other Current Liabilities, Total | 23.043 | 22.38 | 17.634 | 14.047 | 7.048 |
| Total Liabilities | 53.87 | 56.37 | 73.964 | 76.031 | 79.054 |
| Total Long Term Debt | 10.055 | 9.993 | 29.975 | 29.955 | 30.328 |
| Long Term Debt | 10.055 | 9.993 | 29.975 | 29.955 | 30.328 |
| Other Liabilities, Total | 14.004 | 17.417 | 21.202 | 24.804 | 32.602 |
| Total Equity | 7.781 | 19.727 | 16.033 | 25.773 | 36.432 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | |
| Common Stock | 0.032 | 0.031 | 0.027 | 0.027 | 0.027 |
| Additional Paid-In Capital | 325.308 | 321.669 | 304.697 | 302.923 | 302.18 |
| Retained Earnings (Accumulated Deficit) | -317.559 | -301.973 | -288.691 | -277.177 | -265.775 |
| Total Liabilities & Shareholders’ Equity | 61.651 | 76.097 | 89.997 | 101.804 | 115.486 |
| Total Common Shares Outstanding | 31.8893 | 30.7896 | 27.0201 | 26.9489 | 26.7854 |
- Ikgadējs
- Ceturkšņa
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Neto ienākumi/Sākuma Līnija | -43.159 | -31.35 | -30.726 | -26.166 |
| Nauda no Darbības | -28.223 | -21.366 | -21.726 | -17.677 |
| Nauda no Darbības | 3.178 | 2.903 | 2.793 | 1.74 |
| Bezskaidras Naudas Preces | 7.167 | 11.882 | 7.852 | 6.496 |
| Izmaiņas Apgrozāmajā Kapitālā | 4.591 | -4.801 | -1.645 | 0.253 |
| Nauda no Ieguldījumu Darbībām | -2.547 | -2.927 | -1.872 | -0.617 |
| Kapitālie Izdevumi | -2.547 | -2.177 | -1.416 | -0.617 |
| Citi Ieguldījumu Naudas Plūsmas Posteņi, Kopā | 0 | -0.75 | -0.456 | 0 |
| Nauda no Darbībām ar Finansēšanu | 1.262 | 81.131 | 22.972 | 19.032 |
| Naudas Plūsma Finansēšanas Posteņos | -0.5 | -8.249 | -0.119 | -0.283 |
| Akciju Izsniegšana (Atkāpšanās), Neto | 17.112 | 73.34 | 10.047 | 8.55 |
| Parādu Izsniegšana (Atkāpšanās), Neto | -15.35 | 16.04 | 13.044 | 10.765 |
| Neto Izmaiņas Naudā | -29.508 | 56.838 | -0.626 | 0.738 |
| Samaksātie Procenti Naudā | 1.676 | 1.844 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -15.586 | -43.159 | -29.877 | -18.363 | -6.961 |
| Cash From Operating Activities | -13.099 | -28.223 | -18.026 | -10.236 | -11.326 |
| Cash From Operating Activities | 0.908 | 3.178 | 2.323 | 1.523 | 0.746 |
| Non-Cash Items | 2.674 | 7.167 | 4.704 | 5.336 | 3.721 |
| Changes in Working Capital | -1.095 | 4.591 | 4.824 | 1.268 | -8.832 |
| Cash From Investing Activities | -0.352 | -2.547 | -1.906 | -0.864 | -0.516 |
| Capital Expenditures | -0.352 | -2.547 | -1.906 | -0.864 | -0.516 |
| Other Investing Cash Flow Items, Total | 0 | 0 | 0 | 0 | |
| Cash From Financing Activities | -2.834 | 1.262 | 5.625 | 5.229 | 4.951 |
| Financing Cash Flow Items | -4.6 | -0.5 | 0.232 | -0.109 | -0.108 |
| Issuance (Retirement) of Stock, Net | 1.674 | 17.112 | 0.739 | 0.679 | 0.475 |
| Issuance (Retirement) of Debt, Net | 0.092 | -15.35 | 4.654 | 4.659 | 4.584 |
| Net Change in Cash | -16.285 | -29.508 | -14.307 | -5.871 | -6.891 |
| Cash Interest Paid | 0.223 |
| Investora vārds | Investora veids | Nenokārtots procents | Akcijas turējumā | Izmaiņas akcijās | Turēšanas termiņš | Apgrozījuma reitings |
|---|---|---|---|---|---|---|
| Schuler (Jack W) | Individual Investor | 25.5879 | 19952112 | 8695652 | 2022-11-21 | |
| Kennedy (Lawrence T Jr.) | Individual Investor | 19.0156 | 14827404 | 0 | 2023-01-03 | MED |
| Patience (John) | Individual Investor | 9.0025 | 7019695 | 1739130 | 2022-11-21 | LOW |
| Birchview Capital, LP | Investment Advisor | 6.4632 | 5039633 | 2884624 | 2022-12-31 | LOW |
| AIGH Capital Management, LLC. | Private Equity | 5.8936 | 4595512 | -973389 | 2022-12-31 | MED |
| Cawthorn (Robert E) | Individual Investor | 4.6838 | 3652220 | 1723341 | 2022-11-21 | LOW |
| Strobeck (Matthew W) | Individual Investor | 3.7251 | 2904668 | 1304345 | 2022-11-21 | LOW |
| Industrial Development Funding LLC | Corporation | 2.432 | 1896374 | 0 | 2022-03-01 | LOW |
| Worth Venture Partners, LLC | Investment Advisor/Hedge Fund | 1.9211 | 1497963 | 1497963 | 2022-12-31 | HIGH |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 1.4189 | 1106403 | 866747 | 2022-12-31 | LOW |
| Wells Fargo Advisors | Research Firm | 0.9923 | 773725 | 5000 | 2022-12-31 | LOW |
| Essex Investment Management Company, LLC | Investment Advisor/Hedge Fund | 0.4848 | 377994 | -29 | 2022-12-31 | LOW |
| Life Sciences Alternative Financing, L.L.C. | Corporation | 0.3771 | 294053 | 0 | 2022-03-01 | LOW |
| Cannell & Co. | Investment Advisor | 0.2637 | 205605 | 0 | 2022-12-31 | LOW |
| Hutton Scott | Individual Investor | 0.2561 | 199726 | 28499 | 2023-02-09 | HIGH |
| Massarany (Hany) | Individual Investor | 0.1769 | 137934 | 130434 | 2022-11-21 | HIGH |
| Hightower Advisors, LLC | Investment Advisor | 0.175 | 136434 | 136434 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.1617 | 126122 | 2052 | 2022-12-31 | LOW |
| Endurant Capital Management LP | Hedge Fund | 0.1596 | 124430 | -5706 | 2022-12-31 | HIGH |
| Millennium Management LLC | Hedge Fund | 0.1382 | 107788 | -10260 | 2022-12-31 | HIGH |
Kāpēc izvēlēties Capital.com? Mūsu skaitļi runā paši par sevi.
Capital.com Group500K+
Tirgotāji
92K+
Ikmēneša aktīvie klienti
$53M+
Ikmēneša ieguldījumu apjoms
$30M+
Izņemts katru mēnesi
Treidinga kalkulators
Aprēķiniet iespējamo peļņu un zaudējumus, uzsākot CFD darījumu noteiktā dienā (izvēlaties datumu) un slēdzot darījumu citā dienā (izvēlaties datumu).
Tirdzniecības komisija
0
- 1:1
Finanšu svira
1:1
- 20
- 100
- 500
- 1000
- 10000
Investīcija
Darījuma apjoms (Kredītplecs x Investīcija):
Atvēršana
Aizvēršana
Īss Garšs
Biodesix, Inc. Company profile
Par Biodesix, Inc.
Biodesix, Inc. ir Amerikas Savienotajās Valstīs reģistrēts uzņēmums, kas nodarbojas ar asins diagnostikas testu izstrādi un komercializāciju onkoloģijā. Uzņēmuma produkts Biodesix Lung Reflex apvieno genomiskos un proteomiskos asins analīžu rezultātus, lai atklātu abas plaušu vēža puses. Uzņēmuma GeneStrat tests 72 stundu laikā sniedz uz asinīm balstītus mutāciju rezultātus pacientiem ar nesmalto šūnu plaušu vēzi (NSCLC). VeriStrat tests nodrošina uz asinīm balstītu prognozējošu un prognostisku proteomikas informāciju pacientiem ar (NSCLC), kuru glomerulārās filtrācijas ātruma (EGFR) mutāciju tests ir negatīvs (EGFR wild-type) vai kuru EGFR mutāciju statuss nav zināms.
| Industry: | Medical & Diagnostic Laboratories |
Suite 100
2970 Wilderness Place
BOULDER
COLORADO 80301
US
Peļņas Atskaite
- Annual
- Quarterly
Cilvēki arī skatās
Vai joprojām meklējat mākleri, kuram varat uzticēties?
Pievienojieties 500 000+ tirgotājiem visā pasaulē, kuri izvēlējās tirgoties ar Capital.com